Cambridge, UK, 05 January 2023: PhoreMost Ltd., has triggered a milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim. This was achieved by identifying and validating novel targets supporting Boehringer Ingelheim’s ambition to develop first-in-class therapies, to transform patients’ lives.
News
Marks & Clerk are proud to present The IP Driven Start-up e-book, which is released today!
Authored by Robert Lind, leading intellectual property firm Marks & Clerk brings you a pithy summary of the issues facing the IP driven start up and how to deal with these.
This book emphasises what the founders need to put in place at the outset to secure their IP assets and ensure that maximum value is obtained at the point of exit. It also considers the steps that need to be taken to manage growth and avoid IP assets slipping through the net.
We’re helping NeoVac fast-track its revolutionary lipid nanoparticle technology to clinical trials, to make RNA vaccines and therapies more transportable and able to tackle multiple pathogen variants while having fewer side effects compared with existing licensed vaccines.
Cambridge, UK, 3rd January 2023, Astex Pharmaceuticals, UK, congratulates Harren Jhoti, PhD, FRS, FMedSci, its co-founder, President and CEO on being honoured in the 2023 King’s New Year Honours list. Dr Jhoti has been made an Officer of the Order of the British Empire (OBE) for services to Cancer Research and Drug Discovery.
- Key strategic appointment as the Company enters next phase of commercial growth and global expansion of its products and services
- Former CEO, Dr David Hughes, appointed to Scientific Advisory Board
Click here to view the December 2022 edition of The Meeting Place
Asahi Kasei Pharma offers collaborative research opportunities with research funding and our scientists’ contribution through research activities.
Cambridge, UK, 14 December 2022: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, and ThinkCyte K.K, a biotechnology company pioneering novel cell analysis and sorting instruments, today announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI).
AMSBIO announce a new range of different isolation products for fast, scalable, and reproducible purification of Extracellular Vesicles (EV), including exosomes, as well as addressing EV heterogeneity and high throughput solutions for biomarker discovery.
ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women's health, has appointed a project manager to lead the preclinical development of its in-licensed triple negative breast cancer treatment, CLX001.